Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting

Dual antiplatelet therapy with aspirin and a thienopyridine (ticlopidine or clopidogrel) has strikingly improved the results of percutaneous coronary intervention (PCI) through a marked reduction in the rate of stent thrombosis (ST). Emerging data suggest that resistance to antiplatelet treatment may be a risk factor for ST. We report about a patient, aspirin and clopidogrel poor responder, who experienced 4 ST in 10 days. After the second ST, during antiplatelet therapy with aspirin (100 mg/die) and clopidogrel (75 mg/die), the patient's platelet function was investigated with Platelet Function Analyzer 100, VerifyNow P2Y12 System and light transmission aggregometry (LTA). High platelet reactivity and combined resistance to aspirin and clopidogrel were found, and, as a consequence, treatment was switched to clopidogrel 150 mg and aspirin 300 mg/die. In spite of this adjustment, the third ST occurred. Poor responsiveness to aspirin and clopidogrel was still confirmed. Because of combined clopidogrel and aspirin resistance and to unsuccessful PCI treatment, a single coronary artery bypass graft (CABG) was planned. Awaiting surgery, 3 days later, the fourth ST occurred. It is angiographically confirmed and thus, CABG was performed. After CABG, in chronic treatment with aspirin (300 mg/die) and ticlopidine (500 mg/die), no bleeding complications occurred and the patient did not experience recurrent ischemia (2 years follow-up). A better platelet inhibition by ticlopidine than that obtained by clopidogrel was observed. Our case report remarks the importance to identify these poor responder patients as the treatment can be tailored with alternative therapeutic options (ticlopidine, prasugrel, warfarin) and/or different revascularization strategies (CABG)